Curelab Veterinary’s mission is to help pets live longer, healthier, and happier lives.
Investing in Curelab Veterinary aims to support both pets and their owners through the continued relationship the pet owner has with their pet, as 95% of pet owners consider their pet part of the family.
The human-animal bond is defined as a mutually beneficial and dynamic relationship between people and animals that is influenced by behaviors essential to the health and wellbeing of both.
It has been proven that pet ownership provides their owners with many health benefits including: lowered blood pressure, decreased depression, more exercise, lowered risk of a stroke and heart attack, to name a few.
We believe in giving back to humanity and pets while still enjoying a substantial return on investment – a win/win scenario for all.
Every pet owner wishes for their pets to live long lives – however, as pets age, their health issues can become a concern.
Aging is a disease of chronic inflammation, and results in the following:
- Every other dog or cat over the age of 10 will suffer from cancer
- Cancer is the number 1 cause of death in dogs
- 1 in 4 dogs and 1 in 5 cats will develop cancer
- 80% of dogs over 7 and 90% cats over 12 will suffer from osteoarthritis
But thankfully, this soon may change.
ElenaVet® is an anticancer/anti-inflammatory plasmid therapeutic that is poised to revolutionize cancer treatment in dogs and cats, extending the life of these precious family members.
ElenaVet™ is a therapeutic plasmid (supercoiled circular DNA) in which we have inserted a gene-encoding protein p62/SQSTM1.
How does ElenaVet™ work?
ElenaVet™ corrects the tumor microenvironment surrounding cancer cells, making it more favorable for anti-cancer immunity; additionally, ElenaVet™ changes the tumor structure itself, making it harder for metastatic cells to exit the tumor and form new remote lesions.
The grade of a tumor — the cancer grade — is an indication of how quickly it is likely to grow and spread. Tumors of higher grades are more resistant to treatments. Our ElenaVet™ prototype reverted/reduced the tumor grade in five out of six canine mammary cancers; and in one case out of six, the tumor was reverted to a non-cancerous state.
We plan to make ElenaVet™ our first product.
Potential future applications aim to include:
- Metabolic syndrome
FDA and USDA officials have jointly reviewed ElenaVet™’s case and made a decision that ElenaVet™ will go through USDA-CVB. CLV management held a conference call with USDA-CVB officials and learned that ElenaVet™’s path to approval plans consist of the following steps: first, CLV plans to conduct expedited safety studies in the US using a limited number of research dogs. The next step may then be to conduct US efficacy testing for conditional approval. Given the data seen in the previous non-US trials, CLV is not expecting any gross or hematological side-effects and expects similar efficacy seen in previous trials. Curelab Veterinary expects a 24-36 month review period prior to conditional licensure at which point sales can begin.
We publish our results in top peer-reviewed journals.
Curelab Veterinary Launches in Animal Health Sector, Leveraging Technology Licensed from CureLab Oncology
Pilot study of p62 DNA vaccine in dogs with mammary tumors
Plasmid DNA-coding p62 as a bone effective anti-inflammatory/anabolic agent
- Wiley Online Library
p62/SQSTM1 expression in canine mammary tumours: Evolutionary notes - Mariotti - 2019 - Veterinary and Comparative Oncology
p62 /SQSTM1 coding plasmid prevents age related macular degeneration in a rat model
We plan to market our product to veterinarians as an effective, more affordable treatment for breast cancer rather than chemotherapy, although the product may also be used in conjunction with chemotherapy.
Aiming to be affordable for pet owners, 1 round of ElenaVet™ plans to be ~$1K with COGS ~20%; for comparison, 1 round of chemotherapy is $3-5K.
success to date
- Patented in 20+ countries
- Raised $2.5M in 2022
- ElenaVet™ has successfully treated 10 out of 11 dogs with breast cancer
Use of Proceeds
If the offering's maximum amount of $1,234,980 is raised:
|Use||Value||% of Proceeds|
|Compensation for managers||$516,765||41.8%|
|USDA Consultant and Regulatory||$352,340||28.5%|
This is an offering of Class A Common Stock, under registration exemption 4(a)(6), in CureLab Veterinary Inc.. This offering must raise at least $10,000 by February 22, 2023 at 10:59pm ET. If this offering doesn’t reach its target, then your money will be refunded. CureLab Veterinary may issue additional securities to raise up to $1,234,980, the offering’s maximum.
If the offering is successful at raising the maximum amount, then the company’s implied valuation after the offering (sometimes called its post-money valuation) will be:
These financial statements have been reviewed by an independent Certified Public Accountant.
The Offering Statement is a formal description of the company and this transaction. It’s filed with the SEC to comply with the requirements of exemption 4(a)(6) of the Securities Act of 1933.
We’re also required to share links to each of the SEC filings related to this offering with investors.
Understand the Risks
Be sure to understand the risks of this type of investment. No regulatory body (not the SEC, not any state regulator) has passed upon the merits of or given its approval to the securities, the terms of the offering, or the accuracy or completeness of any offering materials or information posted herein. That’s typical for Regulation CF offerings like this one.
Neither Netcapital nor any of its directors, officers, employees, representatives, affiliates, or agents shall have any liability whatsoever arising from any error or incompleteness of fact or opinion in, or lack of care in the preparation or publication of, the materials and communication herein or the terms or valuation of any securities offering.
The information contained herein includes forward-looking statements. These statements relate to future events or to future financial performance, and involve known and unknown risks, uncertainties, and other factors, that may cause actual results to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties, and other factors, which are, in some cases, beyond the company’s control and which could, and likely will, materially affect actual results, levels of activity, performance, or achievements. Any forward-looking statement reflects the current views with respect to future events and is subject to these and other risks, uncertainties, and assumptions relating to operations, results of operations, growth strategy, and liquidity. No obligation exists to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
- Dec 22, 2022Primary offering of $30shares at
- Dec 22, 2022
Ask a Question
Proofread your comment before submitting: once it's posted, you can’t edit or delete it. For the fastest help with the web site, email email@example.com instead of commenting.